Reduction of Sperm DNA Fragmentation by Oral Ginger

January 8, 2014 updated by: Royan Institute

Reduction of Sperm DNA Fragmentation by Oral Ginger (Zingiberofficinale) Extract Treatment

This study is a randomized, double blind, controlled clinical trials assess the efficacy of the ginger oral treatment on sperm DNA fragmentation, sperm parameters and male hormones.

Study Overview

Status

Completed

Conditions

Detailed Description

Sperm DNA fragmentation is known to affect male fertility. Previous findings have suggested the implication of oxidative stress in the etiology of this pathological condition. The present study was designed to find out DNA fragmentation in ejaculated spermatozoa can be reduced by oral treatment with Ginger extract. 71 men with unexplained or Idiopathic infertility were randomized between a Ginger treatment (500 milligram daily for 3months) group and a placebo group.

Sperm DNA fragmentation was evaluated by Terminal deoxyribonucleotidyltransferase-mediated dUTP nick-end labeling assay (TUNEL) before and after treatment. No differences in basic sperm parameters were found between the Ginger treatment and the placebo group before or after treatment. However, the percentage of DNA-fragmented spermatozoa was markedly reduced (P< .005) in the Ginger treatment group after the treatment as compared with the pretreatment values). No difference in the pretreatment and post treatment incidence of sperm DNA fragmentation was observed in the placebo group. These data show that sperm DNA damage can be efficiently treated with oral Ginger extract administered during a relatively short time period.

Study Type

Interventional

Enrollment (Actual)

71

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 50 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • men with idiopathic infertility or unexplained

Exclusion Criteria:

  • history of varicocele, genitourinary inflammation or infection
  • history of cigarette smoking.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: ginger
The patients with infertility that underwent oral administration of ginger.
Oral administration of ginger in patients with infertility.
Other Names:
  • Administration of herbal drug
Placebo Comparator: Placebo
The patients with infertility that receive placebo.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
sperm DNA fragmentation
Time Frame: 3 months
Evaluation the percent of the reduction of sperm DNA fragmentation 3 months after ginger administration.
3 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
male hormones
Time Frame: 3months
Evaluation the effect of ginger on male hormones 3 months after oral administration.
3months
sperm count
Time Frame: 3 months
Evaluation the ginger on sperm count 3 months after oral administration.
3 months
sperm motility
Time Frame: 3 months
Evaluation the effect of ginger on sperm motility 3 months after oral administration.
3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: Ali DaliriHampa, MD, Department of Andrology, Reproductive Biomedicine Center, Royan Institute for Reproductive Biomedicine
  • Study Director: Eyed Jalil Hosseini, MD, Department of Andrology, Reproductive Biomedicine Center, Royan Institute for Reproductive Biomedicine
  • Principal Investigator: Hani Department of Andrology, Reproductive Biomedicine Center, Roya, MSc, Department of Andrology, Reproductive Biomedicine Center, Royan Institute for Reproductive Biomedicine

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2009

Primary Completion (Actual)

September 1, 2010

Study Completion (Actual)

November 1, 2010

Study Registration Dates

First Submitted

January 8, 2014

First Submitted That Met QC Criteria

January 8, 2014

First Posted (Estimate)

January 9, 2014

Study Record Updates

Last Update Posted (Estimate)

January 9, 2014

Last Update Submitted That Met QC Criteria

January 8, 2014

Last Verified

October 1, 2009

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • royan-Emb-017

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Infertility

Clinical Trials on Placebo

Subscribe